文献速递多重用药

综合药物审查对医保受益人潜在不适当药物停用的影响

Impact of comprehensive medication reviews on potentially inappropriate medication discontinuation in Medicare beneficiaries.
PubMed 文献 · J Am Geriatr Soc · 2024-06-03

该回顾性队列研究基于2013—2019年5%医保按服务付费索赔数据与MTM数据,将24,368名接受综合药物审查(CMR)者与24,368名未接受者匹配。结果显示CMR与潜在不适当药物(PIM)停用正相关(aRR 1.26,95%CI 1.20-1.32),且种族或族裔间无差异。

要点

  • CMR与PIM停用正相关,调整后相对风险为1.26(95%CI 1.20-1.32)。
  • CMR对PIM停用的影响未因种族或族裔而不同。
  • CMR后最常停用的PIM为格列美脲、唑吡坦、地高辛、阿米替林和呋喃妥因。

核心结论

  • 在使用PIM的医保受益人中,接受CMR与PIM停用正相关,提示更广泛使用CMR可能有助于所有种族和族裔群体减少PIM。

研究设计与样本

  • 回顾性队列研究,基于2013—2019年5% Medicare按服务付费索赔数据与100% MTM数据文件链接。
  • 纳入符合MTM资格的≥66岁社区居住Medicare Part D受益人,将接受CMR者与未接受者通过序贯分层匹配,各24,368人。

主要发现

  • 匹配队列中位年龄74-75岁,35%为男性,86%-87%为白人受益人,PIM数量中位数为1。
  • 调整分析中CMR接受与PIM停用正相关(aRR 1.26,95%CI 1.20-1.32)。
  • 未发现CMR对PIM停用的影响因种族或族裔而异。
  • CMR后最常停用的PIM为格列美脲、唑吡坦、地高辛、阿米替林和呋喃妥因。

关键数值与推荐

  • CMR接受与PIM停用的调整相对风险为1.26(95%CI 1.20-1.32)。

临床怎么用

  • 对符合MTM资格的老年医保受益人,提供CMR可能促进PIM停用,且该效应在不同种族和族裔群体中一致。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The use of potentially inappropriate medications (PIMs) is associated with increased risk of hospitalizations and emergency room visits and varies by racial and ethnic subgroups. Medicare's nationwide medication therapy management (MTM) program requires that Part D plans offer an annual comprehensive medication review (CMR) to all beneficiaries who qualify, and provides a platform to reduce PIM use. The objective of this study was to assess the impact of CMR on PIM discontinuation in Medicare beneficiaries and whether this differed by race or ethnicity. METHODS: Retrospective cohort study of community-dwelling Medicare Part D beneficiaries ≥66 years of age who were eligible for MTM from 2013 to 2019 based on 5% Medicare fee-for-service claims data linked to the 100% MTM data file. Among those using a PIM, MTM-eligible CMR recipients were matched to non-recipients via sequential stratification. The probability of PIM discontinuation was estimated using regression models that pooled yearly subcohorts accounting for within-beneficiary correlations. The most common PIMs that were discontinued after CMR were reported. RESULTS: We matched 24,368 CMR recipients to 24,368 CMR non-recipients during the observation period. Median age was 74-75, 35% were males, most were White beneficiaries (86%-87%), and the median number of PIMs was 1. In adjusted analyses, CMR receipt was positively associated with PIM discontinuation (adjusted relative risk [aRR]: 1.26, 95% CI: 1.20-1.32). There was no evidence of differential impact of CMR by race or ethnicity. The PIMs most commonly discontinued after CMR were glimepiride, zolpidem, digoxin, amitriptyline, and nitrofurantoin. CONCLUSIONS: Among Medicare beneficiaries who are using a PIM, CMR receipt was associated with PIM discontinuation, suggesting that greater CMR use could facilitate PIM reduction for all racial and ethnic groups.

来源:J Am Geriatr Soc,查看原文。版权归原作者所有。

引用

  1. Hung A, Wilson LE, Smith VA, et al. Impact of comprehensive medication reviews on potentially inappropriate medication discontinuation in Medicare beneficiaries. J Am Geriatr Soc. 2024. PMID: 38826070. doi:10.1111/jgs.19013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。